We identified nine genes whose inhibition may lead to better survival (HR > 1.3; TIGD6, TMED6, APOBEC3D, EP400NL, B3GNT4, ZNF683, FOXD4, FOXD4L1, PKIB) and four genes for which an enhancer may benefit CRC patients’ survival (DDB2, MT1G, CLCN3, CAPS) via genomic instability modulation. The gene discussed is MT1G; the disease is colorectal carcinoma.